Evidence map›Paper›PMID 22808010›Full record

ArticlePloS one2012

Defining an EPOR- regulated transcriptome for primary progenitors, including Tnfr-sf13c as a novel mediator of EPO- dependent erythroblast formation.

Seema Singh, Arvind Dev, Rakesh Verma, Anamika Pradeep, Pradeep Sathyanarayana, Jennifer M Green, Aishwarya Narayanan, Don M Wojchowski

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. STAT5 as a Key Protein of Erythropoietin Signalization.International journal of molecular sciences · 2021
    Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Seema SinghCenter of Excellence in Stem Cell Biology and Regenerative Medicine Maine Medical Center Research Institute, Scarborough, Maine, United States of America.
Arvind Dev
Rakesh Verma
Anamika Pradeep
Pradeep Sathyanarayana
Jennifer M Green
Aishwarya Narayanan
Don M Wojchowski
Maine Medical Center · USMaine Medical Center Research Institute · USAffymax (United States) · USStrand Life Sciences (India) · IN

Funding

WNT SIGNALING IN PREIMPLANTATION EMBRYOP20RR018789 · NCRR · MAINE MEDICAL CENTER · PI WANG, ZACK Z. · 2003 to 2011
$18.9M
IN VITRO STUDIES OF ERYTHROPOIETIN ACTIONR01HL044491 · NHLBI · UNIVERSITY OF NEW HAMPSHIRE · PI WOJCHOWSKI, DON MICHAEL · 1991 to 2020
$4.8M
Novel regulators of stress erythropoiesisR01DK089439 · NIDDK · UNIVERSITY OF NEW HAMPSHIRE · PI WOJCHOWSKI, DON MICHAEL · 2010 to 2017
$2.0M
NCRR NIH HHS P20 RR018789NHLBI NIH HHS NIH R01 HL44491NHLBI NIH HHS R01 HL044491NIDDK NIH HHS NIH R01 DK089439NIDDK NIH HHS R01 DK089439PHS HHS NIH/NCRR P20 RR18789
6 · The paper itself

Abstract

Certain concepts concerning EPO/EPOR action modes have been challenged by in vivo studies: Bcl-x levels are elevated in maturing erythroblasts, but not in their progenitors; truncated EPOR alleles that lack a major p85/PI3K recruitment site nonetheless promote polycythemia; and Erk1 disruption unexpectedly bolsters erythropoiesis. To discover novel EPO/EPOR action routes, global transcriptome analyses presently are applied to interrogate EPO/EPOR effects on primary bone marrow-derived CFUe-like progenitors. Overall, 160 EPO/EPOR target transcripts were significantly modulated 2-to 21.8-fold. A unique set of EPO-regulated survival factors included Lyl1, Gas5, Pim3, Pim1, Bim, Trib3 and Serpina 3g. EPO/EPOR-modulated cell cycle mediators included Cdc25a, Btg3, Cyclin-d2, p27-kip1, Cyclin-g2 and CyclinB1-IP-1. EPO regulation of signal transduction factors was also interestingly complex. For example, not only Socs3 plus Socs2 but also Spred2, Spred1 and Eaf1 were EPO-induced as negative-feedback components. Socs2, plus five additional targets, further proved to comprise new EPOR/Jak2/Stat5 response genes (which are important for erythropoiesis during anemia). Among receptors, an atypical TNF-receptor Tnfr-sf13c was up-modulated >5-fold by EPO. Functionally, Tnfr-sf13c ligation proved to both promote proerythroblast survival, and substantially enhance erythroblast formation. The EPOR therefore engages a sophisticated set of transcriptome response circuits, with Tnfr-sf13c deployed as one novel positive regulator of proerythroblast formation.

Indexed as

TranscriptomeAnimalsBone MarrowCell Cycle ProteinsCell DifferentiationErythroblastsErythropoiesisErythropoietinGene Expression RegulationGene Knock-In TechniquesMiceMice, TransgenicProtein IsoformsReceptors, ErythropoietinReceptors, Tumor Necrosis FactorRNA, MessengerCell Cycle ProteinsErythropoietinProtein IsoformsReceptors, ErythropoietinReceptors, Tumor Necrosis FactorRNA, Messenger

Identifiers

PMID22808010
PMCPMC3396641
OpenAlexW2088834051

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.